106 related articles for article (PubMed ID: 19414946)
21. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Agha A; Bashir K; Anwar E
Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
[TBL] [Abstract][Full Text] [Related]
22. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
Estacio RO; Coll JR; Tran ZV; Schrier RW
Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
[TBL] [Abstract][Full Text] [Related]
23. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Eijkelkamp WB; Zhang Z; Remuzzi G; Parving HH; Cooper ME; Keane WF; Shahinfar S; Gleim GW; Weir MR; Brenner BM; de Zeeuw D
J Am Soc Nephrol; 2007 May; 18(5):1540-6. PubMed ID: 17409317
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics of normotensive renal transplant recipients with microalbuminuria and effects of angiotensin II type I receptor antagonist on urinary albumin excretion.
Satoh S; Horikawa Y; Kakinuma H; Tsuchiya N; Wang L; Kato T; Habuchi T
Int J Urol; 2004 Aug; 11(8):585-91. PubMed ID: 15285746
[TBL] [Abstract][Full Text] [Related]
25. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
Agha A; Amer W; Anwar E; Bashir K
Saudi J Kidney Dis Transpl; 2009 May; 20(3):429-35. PubMed ID: 19414946
[TBL] [Abstract][Full Text] [Related]
26. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
27. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF; Lyle PA;
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
[TBL] [Abstract][Full Text] [Related]
28. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
29. Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B
Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
[TBL] [Abstract][Full Text] [Related]
30. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
31. Renal protection in diabetic patients: benefits of a first-line combination of perindopril-indapamide (Preterax).
Ruilope LM; Segura J
J Hypertens Suppl; 2006 May; 24(3):S9-12. PubMed ID: 16723864
[TBL] [Abstract][Full Text] [Related]
32. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial.
Schrier RW; Estacio RO; Mehler PS; Hiatt WR
Nat Clin Pract Nephrol; 2007 Aug; 3(8):428-38. PubMed ID: 17653121
[TBL] [Abstract][Full Text] [Related]
33. Diabetic nephropathy: common questions.
Thorp ML
Am Fam Physician; 2005 Jul; 72(1):96-9. PubMed ID: 16035688
[TBL] [Abstract][Full Text] [Related]
34. [The effect of captopril therapy on the degree of microalbuminuria in diabetic children and adolescents with incipient nephropathy].
Barkai L; Soós A; Vámosi I
Orv Hetil; 1996 Nov; 137(46):2565-8. PubMed ID: 9005384
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]